Pharmaceuticals & Biotechnology (4570)

19,430.33
   
  • 52 Week High: 24,649.93
  • 52 Week Low: 19,184.55

Latest ShareCast News

GSK's Arexvy approved for wider age range in Japan

By Benjamin Chiou

Date: Friday 22 Nov 2024

(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider age range.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are end of day values only.

 

Price Data

Price 19,430.33
Closing Price Change 171.19
% Change 0.89 %
21-Nov-24 Close 19,430.33

Top Risers

Price Change
HEMO 1.63p +6.6%
AVCT 48.41p +4.1%
ONT 127.30p +3.7%
CIZ 1.96p +3.2%
EAH 67.80p +2.7%
AGY 5.33p +2.6%
EDEN 3.97p +1.7%
GUN 0.12p +1.7%
AZN 10,206.00p +1.4%
HIK 1,898.00p +1.4%

Top Fallers

Price Change
STX 2.82p -4.4%
TCF 0.52p -4.2%
OVB 1.65p -2.9%
IXI 11.69p -2.6%
N4P 0.63p -2.6%
OXB 402.50p -2.4%
SAR 25.40p -2.3%
VAL 1.64p -2.2%
RGT 15.67p -2.1%
VRCI 3.31p -2.0%

Top of Page